Frontline Bruton tyrosine kinase inhibitors are associated with improved response and PFS in primary CNS lymphoma.
Newer tyrosine kinase inhibitors improved survival outcomes and response rates versus standard chemotherapy in primary brain lymphoma patients.
BTKi-based frontline therapy in 85 newly diagnosed PCNSL patients was associated with improved PFS (HR 0.57, 95% CI 0.32-1.00, P=0.048) and higher complete response rates (OR 5.50, P<0.001) vs conventional HD-MTX immunochemotherapy after IPTW-balanced comparison. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Retrospective cohort with IPTW adjustment
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Blood Adv
Why it surfaced
Well-adjusted retrospective Blood Advances study from Sun Yat-sen supporting BTKi as frontline PCNSL therapy; relevant to the growing evidence base for BTK inhibition in CNS lymphoma and PCNSL treatment algorithm refinement.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.